Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F17%3A10373398" target="_blank" >RIV/00064203:_____/17:10373398 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1186/s40658-017-0193-4" target="_blank" >https://doi.org/10.1186/s40658-017-0193-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s40658-017-0193-4" target="_blank" >10.1186/s40658-017-0193-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

Popis výsledku v původním jazyce

Background: Currently, the implementation of dosimetry in molecular radiotherapy (MRT) is not well investigated, and in view of the Council Directive (2013/59/Euratom), there is a need to understand the current availability of dosimetry-based MRT in clinical practice and research studies. The aim of this study was to assess the current practice of MRT and dosimetry across European countries. Methods: An electronic questionnaire was distributed to European countries. This addressed 18 explicitly considered therapies, and for each therapy, a similar set of questions were included. Questions covered the number of patients and treatments during 2015, involvement of medical specialties and medical physicists, implementation of absorbed dose planning, post-therapy imaging and dosimetry, and the basis of therapy prescription. Results: Responses were obtained from 26 countries and 208 hospitals, administering in total 42,853 treatments. The most common therapies were I-131-NaI for benign thyroid diseases and thyroid ablation of adults. The involvement of a medical physicist (mean over all 18 therapies) was reported to be either minority or never by 32% of the responders. The percentage of responders that reported that dosimetry was included on an always/majority basis differed between the therapies and showed a median value of 36%. The highest percentages were obtained for Lu-177-PSMA therapy (100%), Y-90 microspheres of glass (84%) and resin (82%), I-131-mIBG for neuroblastoma (59%), and I-131-NaI for benign thyroid diseases (54%). The majority of therapies were prescribed based on fixed-activity protocols. The highest number of absorbed-dose based prescriptions were reported for Y-90 microsphere treatments in the liver (64% and 96% of responses for resin and glass, respectively), I-131-NaI treatment of benign thyroid diseases (38% of responses), and for I-131-mIBG treatment of neuroblastoma (18% of responses). Conclusions: There is a wide variation in MRT practice across Europe and for different therapies, including the extent of medical-physicist involvement and the implementation of dosimetry-guided treatments.

Název v anglickém jazyce

Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

Popis výsledku anglicky

Background: Currently, the implementation of dosimetry in molecular radiotherapy (MRT) is not well investigated, and in view of the Council Directive (2013/59/Euratom), there is a need to understand the current availability of dosimetry-based MRT in clinical practice and research studies. The aim of this study was to assess the current practice of MRT and dosimetry across European countries. Methods: An electronic questionnaire was distributed to European countries. This addressed 18 explicitly considered therapies, and for each therapy, a similar set of questions were included. Questions covered the number of patients and treatments during 2015, involvement of medical specialties and medical physicists, implementation of absorbed dose planning, post-therapy imaging and dosimetry, and the basis of therapy prescription. Results: Responses were obtained from 26 countries and 208 hospitals, administering in total 42,853 treatments. The most common therapies were I-131-NaI for benign thyroid diseases and thyroid ablation of adults. The involvement of a medical physicist (mean over all 18 therapies) was reported to be either minority or never by 32% of the responders. The percentage of responders that reported that dosimetry was included on an always/majority basis differed between the therapies and showed a median value of 36%. The highest percentages were obtained for Lu-177-PSMA therapy (100%), Y-90 microspheres of glass (84%) and resin (82%), I-131-mIBG for neuroblastoma (59%), and I-131-NaI for benign thyroid diseases (54%). The majority of therapies were prescribed based on fixed-activity protocols. The highest number of absorbed-dose based prescriptions were reported for Y-90 microsphere treatments in the liver (64% and 96% of responses for resin and glass, respectively), I-131-NaI treatment of benign thyroid diseases (38% of responses), and for I-131-mIBG treatment of neuroblastoma (18% of responses). Conclusions: There is a wide variation in MRT practice across Europe and for different therapies, including the extent of medical-physicist involvement and the implementation of dosimetry-guided treatments.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30224 - Radiology, nuclear medicine and medical imaging

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

EJNMMI Physics [online]

ISSN

2197-7364

e-ISSN

—

Svazek periodika

4

Číslo periodika v rámci svazku

December

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

20

Strana od-do

—

Kód UT WoS článku

000416955300001

EID výsledku v databázi Scopus

2-s2.0-85037365313